Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/46597
Campo DC Valoridioma
dc.contributor.authorAspa, Javieren_US
dc.contributor.authorRajas, Olgaen_US
dc.contributor.authorde Castro, Felipe Rodríguezen_US
dc.date.accessioned2018-11-23T06:11:23Z-
dc.date.available2018-11-23T06:11:23Z-
dc.date.issued2008en_US
dc.identifier.issn1465-6566en_US
dc.identifier.urihttp://hdl.handle.net/10553/46597-
dc.description.abstractStreptococcus pneumoniae has been consistently shown to represent the most frequent causative agent of community-acquired pneumonia (CAP) and pneumococcal antibiotic resistance towards different families of antibiotics continues to be a much-debated issue. Microbial resistance causes a great deal of confusion in choosing an empirical treatment for pneumonia and this makes it necessary to know which factors actually determine the real impact of antimicrobial resistance on the outcome of pneumococcal infections. Several different aspects have to be taken into account when analyzing this matter, such as the study design, the condition of the patient at the time of diagnosis, the choice of the initial antimicrobial regimen (combination or monotherapy) and the pharmacokinetic/pharmacodynamic variables of the chosen antibiotic. It is generally accepted that in the treatment of beta-lactam-resistant pneumococcal infections, the use of standard antipneurnococcal beta-lactam agents is unlikely to impact negatively on the outcome of CAP when appropriate agents are given in sufficient doses. As a general rule, for infections with penicillin-sensitive strains, penicillin or an aminopenicillin in a standard dosage will be effective; in the cases of strains with intermediate resistance, beta-lactam agents are still considered appropriate treatment although higher dosages are recommended; finally, infections with isolates of high-level penicillin resistance should be treated with alternative agents such as the third-generation cephalosporins or the new antipneurnococcal fluoroquinolones. In areas of high prevalence of high-level macrolide resistance, empirical monotherapy with a macrolide is not optimal for the treatment of hospitalised patients with moderate or moderately-severe CAP. Fluoroquinolones are considered to be excellent antibiotics in the treatment of pneumococcal CAP in adults, but their general recommendation has been withheld due to fears of a widespread development of resistance. Most international guidelines recommend combination therapy (beta-lactam plus a macrolide) for the treatment of hospitalised patients with CAP.en_US
dc.languageengen_US
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_US
dc.sourceExpert Opinion on Pharmacotherapy[ISSN 1465-6566],v. 9, p. 229-241en_US
dc.subject32 Ciencias médicasen_US
dc.subject320508 Enfermedades pulmonaresen_US
dc.subject.otherLevel Fluoroquinolone Resistanceen_US
dc.subject.otherCombination Antibiotic-Therapyen_US
dc.subject.otherRespiratory-Tract Infectionsen_US
dc.subject.otherBeta-Lactam Antibioticsen_US
dc.subject.otherIn-Vitro Resistanceen_US
dc.subject.otherStreptococcus-Pneumoniaeen_US
dc.subject.otherPenicillin-Resistanten_US
dc.subject.otherClinical-Relevanceen_US
dc.subject.otherRisk-Factorsen_US
dc.subject.otherMacrolide Resistanceen_US
dc.titlePneumococcal antimicrobial resistance: Therapeutic strategy and management in community-acquired pneumoniaen_US
dc.typeinfo:eu-repo/semantics/reviewen_US
dc.typeArticleen_US
dc.identifier.doi10.1517/14656566.9.2.229en_US
dc.identifier.scopus39049113306-
dc.identifier.isi000252878400006-
dc.contributor.authorscopusid6602555827-
dc.contributor.authorscopusid6505890335-
dc.contributor.authorscopusid55942667000-
dc.description.lastpage241en_US
dc.description.firstpage229en_US
dc.relation.volume9en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Reseñaen_US
dc.contributor.daisngid952601-
dc.contributor.daisngid1134484-
dc.contributor.daisngid464249-
dc.description.numberofpages13en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Aspa, J-
dc.contributor.wosstandardWOS:Rajas, O-
dc.contributor.wosstandardWOS:de Castro, FR-
dc.date.coverdateEnero 2008en_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.description.jcr2,077
dc.description.jcrqQ3
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Patología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-6812-2739-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRodríguez De Castro, Felipe Carlos B.-
Colección:Reseña
Vista resumida

Citas SCOPUSTM   

34
actualizado el 24-mar-2024

Citas de WEB OF SCIENCETM
Citations

33
actualizado el 25-feb-2024

Visitas

42
actualizado el 06-ene-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.